The gift sets up a scholarship, an endowed chair, and a lecture series. Photo via UH.edu

A recent gift to the University of Houston will provide support to a couple colleges on campus, including an endowed chair, a scholarship, and a lecture series.

Thomas Michael Panos Family Estate donated $4.5 million — and was matched with an additional $2 million by the University's new "$100 Million Challenge" Aspire Fund. It's the first matched gift of the new fund. The gift includes $2 million to create the Panos Family Endowed Chair in Mechanical Engineering, $2 million to establish a scholarship endowment beginning in 2022 to support need- and merit-based scholarships for full-time undergraduate or graduate students across UH, and $500,000 to support "The Panos Family Endowed Lecture in Equity and Social Justice" in the College of Liberal Arts and Social Sciences.

"We are incredibly grateful for the generosity of the Thomas Michael Panos Family Estate. This significant gift will not only help fuel academic success through innovation and discovery, but will support our ability to recruit renowned faculty and expand thought leadership," says Paula Myrick Short, UH senior vice president for academic affairs and provost, in the release. "The additional support for an equity and social justice lecture series is an especially timely and important part of our efforts to increase visibility around these issues."

Thomas Michael Panos emigrated to Houston from Greece and only had a sixth-grade education. His sons — Mike and Gus Panos — both earned college degrees in engineering.

"They were the kind of people who would help anybody," says Scott Harbers, who lived next door to the Panos family decades ago in what is now Midtown Houston, in the release. "As a family of immigrants, I know they would appreciate the diversity of the student body at the University of Houston. They had a tremendous interest in education and equal rights. I'm hopeful that this gift will help advance the lives of students who need help to complete their studies."

The $100 Million Challenge initiative was established in fall of 2019 thanks to an anonymous $50 million donation to the school, and the campaign is set on inspiring another $50 million in support of four areas that will address issues with major societal impact: sustainable energy and energy security, resilient infrastructure and smart cities, population health, and global engagement. Donors who commit $2 million to go toward an endowed chair will have their gifts matched through the program.

"The '$100 Million Challenge' is a transformational initiative to propel our academic enterprise to unprecedented levels of distinction, and this first matching gift launches us," says Eloise Brice, vice president for university advancement, in the release. "The work and research being done at UH, and accelerated through the Challenge, will have a tremendous impact on the quality of life for all Houstonians."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”